Home

Ascendis Pharma A/S - American Depositary Shares (ASND)

190.35
+0.00 (0.00%)
NASDAQ · Last Trade: Aug 8th, 7:15 AM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close190.35
Open-
Bid189.00
Ask197.00
Day's RangeN/A - N/A
52 Week Range111.09 - 190.35
Volume9
Market Cap10.88B
PE Ratio (TTM)-
EPS (TTM)-
Dividend & YieldN/A (N/A)
1 Month Average Volume481,663

Chart

About Ascendis Pharma A/S - American Depositary Shares (ASND)

Ascendis Pharma is a biotechnology company focused on developing innovative medicines using its proprietary TransCon technology platform. The company aims to address unmet medical needs, particularly in the areas of endocrine diseases and rare disorders, by creating optimally dosed therapies that enhance the bioavailability and efficacy of existing therapies. Through its robust pipeline, Ascendis Pharma is committed to advancing new treatment options that improve patient outcomes and quality of life, leveraging its expertise in drug development and deep understanding of biological mechanisms. Read More

News & Press Releases

Ascendis (ASND) Q2 2025 Earnings Call Transcriptfool.com
Via The Motley Fool · August 7, 2025
Earnings Scheduled For August 7, 2025benzinga.com
Via Benzinga · August 7, 2025
What's Driving the Market Sentiment Around Ascendis Pharma?benzinga.com
Via Benzinga · August 6, 2025
What's Driving the Market Sentiment Around Ascendis Pharma?benzinga.com
Via Benzinga · August 4, 2025
$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Todaybenzinga.com
Via Benzinga · July 28, 2025
Here's How Much $1000 Invested In Ascendis Pharma 10 Years Ago Would Be Worth Todaybenzinga.com
Via Benzinga · July 22, 2025
$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Todaybenzinga.com
Via Benzinga · July 7, 2025
Peering Into Ascendis Pharma's Recent Short Interestbenzinga.com
Via Benzinga · July 3, 2025
Is Ascendis Pharma Gaining or Losing Market Support?benzinga.com
Via Benzinga · June 3, 2025
If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Todaybenzinga.com
Via Benzinga · May 29, 2025
$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Todaybenzinga.com
Via Benzinga · June 12, 2025
If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Todaybenzinga.com
Via Benzinga · May 21, 2025
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 15 Yearsbenzinga.com
Via Benzinga · May 6, 2025
This Twilio Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Mondaybenzinga.com
Via Benzinga · May 5, 2025
Earnings Scheduled For May 1, 2025benzinga.com
Via Benzinga · May 1, 2025
A Glimpse of Ascendis Pharma's Earnings Potentialbenzinga.com
Via Benzinga · April 30, 2025
If You Invested $1000 In This Stock 15 Years Ago, You Would Have This Much Todaybenzinga.com
Via Benzinga · March 4, 2025
Here's How Much $100 Invested In Ascendis Pharma 10 Years Ago Would Be Worth Todaybenzinga.com
Via Benzinga · February 19, 2025
Why ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) could fit Mark Minervini’s high-growth criteriachartmill.com
A fundamental and technical analysis of (NASDAQ:ASND): Is ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) suited for high growth investing?
Via Chartmill · April 28, 2025
If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Todaybenzinga.com
Via Benzinga · April 15, 2025
Does ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) show the characteristics of a Minervini super stock?chartmill.com
A fundamental and technical analysis of (NASDAQ:ASND): Why the high growth investor may take a look at ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND).
Via Chartmill · April 4, 2025
Looking Into Ascendis Pharma's Recent Short Interestbenzinga.com
Via Benzinga · March 26, 2025
Here's How Much $100 Invested In Ascendis Pharma 15 Years Ago Would Be Worth Todaybenzinga.com
Via Benzinga · March 25, 2025
Is ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) a Minervini-style stock?chartmill.com
A fundamental and technical analysis of (NASDAQ:ASND): Why the high growth investor may take a look at ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND).
Via Chartmill · March 14, 2025
Why Is BioMarin Stock Trading Higher On Thursday?benzinga.com
BioMarin exceeded Q4 earnings expectations, raised 2025 guidance, and projected strong Voxzogo growth. Analysts increased price targets following the results.
Via Benzinga · February 20, 2025